2. The Face of Oral Cancer
Kills 1 person/hour
in North America
50% Mortality Rate
within 5 years
Survivors = Poor
quality of life
ROGER EBERT 1942-2013
3. The Problem: Late Detection
Visual assessment methods of precancerous lesions
unchanged in the last 100 years
1910 2014
More than 50% of high-risk lesions are missed!
4. 3. Report
Tool for clinicians to decide on
personalized treatment:
Detecting Cancer BEFORE it happens
with 90% Predictive Value
The Solution: Straticyte™ Test
2. Score
Accurately measures individual probability
of cancer within the next 5 years
1. Test
Patent-protected biomarkers to objectively
assess risk of pre-cancerous oral lesions
High
Risk
65%
9. Success Factors and Traction
Traction Milestones
Product V.1.0
Validated clinical
V2.0
Expanded clinical
Marketing Market Research done
Local Advisory Board
Health Economics
International Advisory Board
Sales Ontario Test Market
Exceptional need
Canadian Roll-Out
US launch
People Full time Management Sales Manager
Product development ass.
Funding $ 750k committed $3 Million
10. 2014 2015 2016
Automated test
Ontario Market Test
$1.0M financing
European Partner
$1.0M financing
Roadmap to market –Risk Mitigation
Economic Study
Canada Roll-Out
USA pilot Site
Asian Partner
$0.75M financing
11. Target Company Acquirer Date Value
($mm)
Revenue
Multiple
BioFire Molecular Dx BioMerieux Sept 2013 $450 6x
GenturaDx Molecular Dx Luminex July 2012 $50 Pre-revenue
Cellestis Molecular Dx Qiagen NV April 2011 $335 8.4X
Athena Dx Molecular Dx Quest Feb 2011 $700 7.0X
Clarient Cancer Dx GE Medical Oct 2010 $580 7.0X
Exit Strategy: Targeting15x ROI at year 5
12. Experienced Management with
International Reach
Dr. Mario Thomas, PhD, DSA, C.Dir.
President
Dr. Kenneth Pritzker, MD, FRCPC
CEO
Extensive experience in novel medical
diagnostics. Former Head of Pathology at Mount-
Sinai Hospital
Dr. Ranju Ralhan, PhD, FNAMS,
Chief Scientific Officer
CIHR Rx&D Chair in Advanced Cancer
Diagnostics, Professor, Department of
Otolaryngology, University of Toronto
John Jordan, MBA, CPA, CMA
Chief Financial Officer
Experience in building technology companies
Key Hire
Sales Manager
Will expand Canadian launch plan in Q1 2015
13. Scientific and Clinical Advisors
Michael Siu
PhD, F.R.S.C.
VP Research, University of Windsor
Chair, Ontario Cancer Biomarker Network
Chair, Canadian National Proteomics Network
David Mock
DDS, PhD, FRCD(C)
Retired Professor, oral pathology
Former Dean, Faculty of Dentistry, University of Toronto
Ian Witterick
MD, MSC, FRCSC
Professor and Chair, Department of Otolaryngology
and Head & Neck Surgery, University of Toronto.
Barrie Renick
DDS, OMFS, dip. Oral path., dip. Oral surg., M.R.D.C. (C)
Oral Maxillofacial Surgeon with extensive clinical practice
New Market, Ontario
14. For more information contact:
Mario Thomas
President
t. (647) 466-8008
e. mthomas@proteocyte.com
Thank You
Editor's Notes
Bonjour tout le monde. Merci d’avoir vote pour nous!
My name is Mario Thomas and I am president of Proteocyte Diagnostics
For a moment, imagine y the surgeon has just informed you have oral cancer and that you unfortunately have a 1 in 2 chance of dying within 5 years. He has also informed you that if you are lucky enough to survive, for the rest of your life you will be disfigured, will have a speech impairment and will probably eat through a straw.
The problem is that most of the time, oral cancer is detected at a too late. This is because that the standard visual assessment methods for identifying precancerous oral lesions have not advanced much in 100 years. These methods are subjective and lack accuracy. The result is that about 50% of high-risk lesions are missed and will progress to cancer leading unnecessary deaths and suffering
1.This is why we have invented Straticyte to detect oral cancer before it happens with 90% accuracy.
2. Straticyte is a patent-protected molecular diagnostic test that measures protein biomarker in precancerous lesions adn can predict the probability of progression to cancer within the next 5 years with objectivity and accuracy
3. We can then provide a report to clinicians to decide on the best personalized treatment dependent on the risk level
The opportunity is huge.
3.3M oral lesions in the more developed world translate into and addressable market close to $1B.
Our 2020 sales will reach $100M
The potential ROI for today’s investors is greater than 15X based on 5 times EBIDTA
Proteocyte has a formidable advantage against the only competition: standard of care.
We have strong intellectual property protection with many patents and trade secrets alike
Our go-to-market startegy is simple.
Direct sales in North-America and strategic partners in other countries.
The business model is billable, scalable and profitable. The patient or the insurance company pays for the test at $300 retail and the fees are transferred to the oral surgeon, oral pathology lab and Proteocyte.
We have traction on all 5 key success factors.
Our initial product is validated by clinical results and we are expanding the clinical studies
The market research is done and we are now working on a health economics study and expanding our advisory board internationally
We are implementing now a market test in Ontario and will roll-out in Canada in 2015 stating revenue generation
Beyond the current raise , we estimate that $3M will be required until profitability
Lastly we will have on board a sales manager in 2015 to grow the business
And we have the team to make this happen:
Ken Pritsker is former head of pathology at Mt-Sinai Hopsital.
Dr. Ralhan is a world authority is cancer biomarkers
John Jordan here with us is very experienced in growing technology companies
Finally I bring international commercial experience from large and small companies
Terry Colgan
Je vous remercie de votre attention, surtout que cet evenement est ici a Quebec ma ville natale ou j’ai grandi!
Thank you very much for your attention.
I hope that you find this opportunity as attractive as we do!
